292 related articles for article (PubMed ID: 25994056)
1. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes.
Yao L; Shen H; Laird PW; Farnham PJ; Berman BP
Genome Biol; 2015 May; 16(1):105. PubMed ID: 25994056
[TBL] [Abstract][Full Text] [Related]
2. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T; Tekpli X; Mathelier A; Wang S; Nebdal D; Dhakal HP; Sahlberg KK; Schlichting E; ; Børresen-Dale AL; Borgen E; Naume B; Eskeland R; Frigessi A; Tost J; Hurtado A; Kristensen VN
Nat Commun; 2017 Nov; 8(1):1379. PubMed ID: 29123100
[TBL] [Abstract][Full Text] [Related]
4. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers.
Li X; Chen S; Sun T; Xu Y; Chen Y; Liu Y; Xiang R; Li N
Clin Lab; 2014; 60(6):909-18. PubMed ID: 25016694
[TBL] [Abstract][Full Text] [Related]
7. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
Laganière J; Deblois G; Lefebvre C; Bataille AR; Robert F; Giguère V
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11651-6. PubMed ID: 16087863
[TBL] [Abstract][Full Text] [Related]
8. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylome and chromatin interactome identify abnormal enhancer to be risk factor of breast cancer.
Wang Y; Hao DP; Li JJ; Wang L; Di LJ
Oncotarget; 2017 Jul; 8(27):44705-44719. PubMed ID: 28621677
[TBL] [Abstract][Full Text] [Related]
10. Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines.
Cao Q; Anyansi C; Hu X; Xu L; Xiong L; Tang W; Mok MTS; Cheng C; Fan X; Gerstein M; Cheng ASL; Yip KY
Nat Genet; 2017 Oct; 49(10):1428-1436. PubMed ID: 28869592
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
12. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.
Hamdan FH; Johnsen SA
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12343-E12352. PubMed ID: 30541891
[TBL] [Abstract][Full Text] [Related]
13. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.
Halmos B; Bassères DS; Monti S; D'Aló F; Dayaram T; Ferenczi K; Wouters BJ; Huettner CS; Golub TR; Tenen DG
Cancer Res; 2004 Jun; 64(12):4137-47. PubMed ID: 15205324
[TBL] [Abstract][Full Text] [Related]
14. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
15. Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering.
Zhang Y; Zhang D; Li Q; Liang J; Sun L; Yi X; Chen Z; Yan R; Xie G; Li W; Liu S; Xu B; Li L; Yang J; He L; Shang Y
Nat Genet; 2016 Sep; 48(9):1003-13. PubMed ID: 27500525
[TBL] [Abstract][Full Text] [Related]
16. Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes.
Kim K; Yang W; Lee KS; Bang H; Jang K; Kim SC; Yang JO; Park S; Park K; Choi JK
Nucleic Acids Res; 2015 Jul; 43(12):5716-29. PubMed ID: 26001967
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of transcription factors and targets co-expression profiles reveals reduced correlation between transcription factors and target genes in cancer.
Liang J; Cui Y; Meng Y; Li X; Wang X; Liu W; Huang L; Du H
Funct Integr Genomics; 2019 Jan; 19(1):191-204. PubMed ID: 30251028
[TBL] [Abstract][Full Text] [Related]
19. FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner.
Milan M; Balestrieri C; Alfarano G; Polletti S; Prosperini E; Spaggiari P; Zerbi A; Diaferia GR; Natoli G
EMBO J; 2019 Oct; 38(20):e102161. PubMed ID: 31531882
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers.
Sérandour AA; Avner S; Percevault F; Demay F; Bizot M; Lucchetti-Miganeh C; Barloy-Hubler F; Brown M; Lupien M; Métivier R; Salbert G; Eeckhoute J
Genome Res; 2011 Apr; 21(4):555-65. PubMed ID: 21233399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
